CVS and Walgreens lift limits on at-home COVID-19 testsEnjaymo (sutimlimab) approved for use in adults with cold agglutinin diseaseThe FDA’s draft guidance for development of non-opioid analgesics is open for public comments until April 11th, 2022SURPASS-5 shows promising results for A1c lowering and weight loss at 40-weeks with tirzepatideMark Cuban’s CostPlus Drug Company has launched with limited formularyOshin O. CVs, Walgreens remove limits on at-home covid-19 tests. TheHill. https://thehill.com/policy/healthcare/public-global-health/593033-cvs-walgreens-remove-limits-on-at-home-covid-19-tests. Published February 6, 2022. Accessed February 10, 2022.Enjaymo [package insert]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf?utm_medium=email&utm_source=govdelivery. Revised February 2022.Cold agglutinin disease. NORD (National Organization for Rare Disorders). https://rarediseases.org/rare-diseases/cold-agglutinin-disease/#:~:text=Cold%20agglutinin%20disease%20(CAD)%20is,subtype%20of%20autoimmune%20hemolytic%20anemia. Published November 17, 2020. Accessed February 10, 2022.Commissioner of the FDA takes steps aimed at fostering development of non-addictive alternatives to opioids for acute pain management. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-takes-steps-aimed-fostering-development-non-addictive-alternatives-opioids-acute-pain-management?utm_campaign=&utm_content=1644424858&utm_medium=FDA%2CU.S.%2BFood%2Band%2BDrug%2BAdministration&utm_source=facebook%2Clinkedin. Accessed February 10, 2022.Center for Drug Evaluation and Research. Development of non-opioid analgesics for acute pain; draft guidance fo. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-acute-pain-draft-guidance-industry. Accessed February 10, 2022.Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes. JAMA. 2022;327(6):534. doi:10.1001/jama.2022.0078Costplusdrugs.com. https://costplusdrugs.com/. Accessed February 10, 2022.Listen to our podcast: Pharm5Watch us on TikTok: @LizHearnPharmDFollow us on Twitter: @LizHearnPharmD
View all episodes
